Sermorelin / GHRP-6 / GHRP-2 Blend
Also known as: Sermorelin & GHRP-6 & GHRP-2, Viking 1
A triple research blend pairing the GHRH analog Sermorelin with two ghrelin-receptor agonists, GHRP-6 and GHRP-2. It is studied for maximal synergistic stimulation of endogenous growth hormone.
Last updated
Mechanism of Action
Sermorelin (GHRH 1-29) binds the pituitary GHRH receptor to promote GH synthesis and release, while GHRP-6 and GHRP-2 both activate the GHS-R1a (ghrelin) receptor to evoke additional GH pulses and suppress somatostatin. Combining a GHRH analog with two complementary GHRPs is intended to maximize the amplitude of pulsatile GH secretion. The blend leverages multiple receptor inputs to drive downstream hepatic IGF-1 production while preserving the natural feedback architecture of the GH axis.
- Half-life
- Mixed: Sermorelin ~10-20 minutes, GHRP-6 ~15-60 minutes, GHRP-2 ~30-60 minutes
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Studied for maximal synergistic GH release
- Investigated for improved recovery and tissue repair
- Examined for lean body mass support
- Researched for appetite stimulation via dual GHRP input
- Studied for enhanced slow-wave sleep
- Investigated for IGF-1 elevation through pituitary pathways
Potential Side Effects
- Pronounced increase in appetite from dual GHRP activity
- Injection-site irritation or transient swelling
- Water retention and tingling in extremities
- Transient flushing or lightheadedness
- Possible elevation of cortisol and prolactin
Common Dosing
Research-literature triple blends are studied at approximately 100-200 mcg of each component per administration, 1-2 times daily, often before sleep or fasted. For research-use only; not personal medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active malignancy or history of cancer
- Pregnancy or breastfeeding
- Known hypersensitivity to GHRH or GHRP analogs
Sermorelin / GHRP-2 Blend
A research blend pairing the GHRH analog Sermorelin with the growth hormone-releasing peptide GHRP-2. The combination is studied for synergistic stimulation of endogenous growth hormone.
Sermorelin / GHRP-6 Blend
A research blend combining the GHRH analog Sermorelin with the ghrelin-receptor agonist GHRP-6. It is studied for synergistic growth hormone release and appetite stimulation.
Sermorelin / Ipamorelin Blend
A widely studied research blend combining the GHRH analog Sermorelin with the highly selective ghrelin-receptor agonist Ipamorelin. It is examined for clean, synergistic growth hormone release with minimal off-target effects.
- View
GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers
1995
- View
Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone
1990
- View
Determinants of GH-releasing hormone and GH-releasing peptide synergy in men
2009
- View
GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans
1996